### Nepal

#### Tuberculosis profile

**Population 2018**: 28 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>42 (37–48)</td>
<td>151 (133–170)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.38 (0.32–0.45)</td>
<td>1.4 (1.1–1.6)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>1.4 (0.77–2.3)</td>
<td>5 (2.8–6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>5.4 (3.8–7.3)</td>
<td>19 (13–26)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.093 (0.071–0.12)</td>
<td>0.33 (0.25–0.42)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 2.2% (1.1–3.6)
- Previously treated cases: 15% (9.6–22)

**TB case notifications, 2018**

- Total new and relapse: 31 855
- % tested with rapid diagnostics at time of diagnosis: 69%
- % with known HIV status: 71%
- % pulmonary: 69%
- % bacteriologically confirmed**: 80%
- % children aged 0-14 years: 5%
- % women: 34%
- % men: 61%
- Total cases notified: 32 474

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 75% (67–85)
- TB patients facing catastrophic total costs: 13% (9–18)

**TB/HIV care in new and relapse TB patients, 2018**

- % tested with rapid diagnostics at time of diagnosis: 69%
- % with known HIV status: 71%
- % pulmonary: 69%
- % bacteriologically confirmed**: 80%
- % children aged 0-14 years: 5%
- % women: 34%
- % men: 61%
- % on antiretroviral therapy: 190 (95%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 50%
  - New cases: 50%
  - Previously treated cases: 56%

**Laboratory-confirmed cases**

- MDR/RR-TB: 669, XDR-TB: 29
- Patients started on treatment**: MDR/RR-TB: 400, XDR-TB: 20
- MDR/RR-TB cases tested for resistance to second-line drugs: 412

**Treatment success rate and cohort size**

- Success: 91% 31 219
- Cohort: 93% 31 219

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 9.4% (8.6–10)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.6–10)

**TB financing, 2019**

- National TB budget (US$ millions): 20
  - Funding source: 39% domestic, 38% international, 24% unfunded

*Ranges represent uncertainty intervals

**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

**Calculated for pulmonary cases only

*Includes cases with unknown previous TB treatment history

**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Generated: 2020-04-11

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Data: www.who.int/tb/data